Sam Brusco, Associate Editor10.11.22
Roche has launched Anti-FRAME (EPR 20330) Rabbit Monoclonal Primary Antibody to identify PRAME (PReferentially expressed Antigen in Melanoma) expression in tissue samples from patients with suspected melanoma.
The PRAME protein is expressed in most melanomas. The PRAME Antibody can help differentiate between benign and malignant lesions—if PRAME expression occurs, it suggests a malignant lesion.
“Every four minutes, one person dies from skin cancer. However, when detected early, localized melanoma is highly curable with a simple surgical excision,” Thomas Schinecker, CEO of Roche Diagnostics told the press. “Identifying this critical biomarker helps clinicians determine if their patient has melanoma. We’re proud to add the PRAME assay to our already comprehensive test menu of dermatology biomarkers that help inform a patient’s diagnosis and treatment.”
A hematoxylin and eosin (H&E) stain of the patient’s tissue sample is the first test used to evaluate a potential melanocytic lesion but not all melanomas are easily diagnosed using the test alone. PRAME expression by immunohistochemistry can complement findings from routine tests.
The PRAME protein is expressed in most melanomas. The PRAME Antibody can help differentiate between benign and malignant lesions—if PRAME expression occurs, it suggests a malignant lesion.
“Every four minutes, one person dies from skin cancer. However, when detected early, localized melanoma is highly curable with a simple surgical excision,” Thomas Schinecker, CEO of Roche Diagnostics told the press. “Identifying this critical biomarker helps clinicians determine if their patient has melanoma. We’re proud to add the PRAME assay to our already comprehensive test menu of dermatology biomarkers that help inform a patient’s diagnosis and treatment.”
A hematoxylin and eosin (H&E) stain of the patient’s tissue sample is the first test used to evaluate a potential melanocytic lesion but not all melanomas are easily diagnosed using the test alone. PRAME expression by immunohistochemistry can complement findings from routine tests.